

Noninvasive Evaluation of Antiangiogenic Effect in a Mouse Tumor Model by DCE-MRI with Gd-DTPA Cystamine Copolymers

Xueming Wu,[†] Eun-Kee Jeong,[‡] Lyska Emerson,[§] John Hoffman,^{||}
Dennis L. Parker,[‡] and Zheng-Rong Lu^{*,†,⊥}

Department of Pharmaceutics and Pharmaceutical Chemistry, Department of Radiology, Department of Pathology, and Molecular Imaging Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84108, and Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106

Received June 12, 2009; Revised Manuscript Received November 19, 2009; Accepted December 3, 2009

Abstract: The efficacy of polydisulfide-based biodegradable macromolecular Gd(III) complexes, Gd-DTPA cystamine copolymers (GDCC), for assessing tumor microvascular characteristics and monitoring antiangiogenesis therapy was investigated in a mouse model using dynamic contrast-enhanced MRI (DCE-MRI). The mice bearing human colon tumor xenografts were intraperitoneally injected with an antiangiogenesis agent Avastin three times in a week at a dose of 200 μ g/mouse. DCE-MRI with GDCC of 40 kDa (GDCC-40) was performed before and at 36 h after the first treatment with Avastin and at the end of treatment (7 days). Gd(DTPA-BMA) was used as a low molecular weight control. The tumor vascular parameters, endothelial transfer coefficient K^{trans} and fractional plasma volume f^{PV} , were calculated from the DCE-MRI data with a two-compartment model. The K^{trans} and f^{PV} in tumor periphery estimated by DCE-MRI with GDCC-40 before and after the antiangiogenesis treatment correlated well to tumor growth before and after the treatment in the tumor model. In contrast, the parameters estimated by Gd(DTPA-BMA) did not show significant correlation to the therapeutic efficacy. This study demonstrates that DCE-MRI with the biodegradable macromolecular MRI contrast agent can provide effective assessment of the antiangiogenic efficacy of Avastin in the animal tumor model based on measured vascular parameters in tumor periphery.

Keywords: DCE-MRI; biodegradable macromolecular contrast agent; (Gd-DTPA) cystamine copolymers; antiangiogenic therapy; Avastin

Introduction

Angiogenesis, recruitment of neovasculature, is crucial for tumor growth and metastasis.^{1–3} Several growth factors have

been identified as possible regulators of angiogenesis.^{1,4} One of most important regulators of angiogenesis is vascular endothelial growth factor (VEGF).⁵ Various inhibitors of VEGF have been developed to inhibit tumor growth by blocking tumor angiogenesis,⁶ including Avastin, a humanized anti-VEGF monoclonal antibody.^{7–11} Development of effective imaging technology for noninvasive assessment of the therapeutic efficacy of antiangiogenic agents is critical for the preclinical and clinical development of new effective antiangiogenesis agents and for the clinical management of antiangiogenesis therapies. Dynamic contrast enhanced (DCE) MRI is a noninvasive imaging modality that can quantitatively measure tumor vascularity and tumor vascular parameters. DCE-MRI has been developed as a powerful tool for tumor characterization¹² and assessing early efficacy of

* Correspondence: Dr. Zheng-Rong Lu, Department of Biomedical Engineering, Wickenden Building, Room 427, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-7207. Phone: 216-368-0187. Fax: 216-368-4969. E-mail: zxl125@case.edu.

[†] Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah.

[‡] Department of Radiology, University of Utah.

[§] Department of Pathology, University of Utah.

^{||} Molecular Imaging Program, Huntsman Cancer Institute, University of Utah.

[⊥] Case Western Reserve University.

anticancer therapies, including antiangiogenesis therapy.¹³ Accurate and noninvasive evaluation of therapeutic efficacy is crucial to monitor and guide efficacious cancer treatment.

It has been shown that the size of MRI contrast agents is important for accurate characterization of tumor vascular parameters with DCE-MRI. Currently, most DCE-MRI studies are performed using low molecular contrast agents.¹⁴ These agents rapidly diffuse from the vascular compartment to the interstitial space, resulting in overestimated tumor vascular parameters. They extravasate nonselectively through normal and lesion vasculature, which limits their ability to distinguish between normal and tumor tissues in DCE-MRI.¹⁵ Macromolecular MRI contrast agents do not extravasate

across the normal vasculature and can selectively penetrate tumor vasculature due to tumor vascular hyperpermeability. Several preclinical studies have shown that macromolecular MRI contrast agents are effective for quantitative characterization of tumor vascularity in DCE-MRI.^{15,16} DCE-MRI with macromolecular contrast agents can effectively differentiate benign tumors from malignant tumors and accurately evaluate tumor response to anticancer treatment in animal models.^{17–19} However, macromolecular agents are not approved for clinical applications because of their slow and incomplete elimination, which may result in toxic side effects due to long-term tissue retention of toxic Gd(III) ions in the body.²⁰

Recently, we have developed a class of polydisulfide-based macromolecular Gd(III) complexes as biodegradable macromolecular MRI contrast agents to facilitate the excretion of Gd(III) chelates after the MRI examinations.^{21–24} These agents initially behave as macromolecular agents for effective enhancement in tumor tissues, and then gradually degrade into low molecular weight Gd(III) complexes, which rapidly

- (1) Shibuya, M. Signal transduction of VEGF receptors toward angiogenesis. In *Angiogenesis: From Basic Science to Clinical Applications*; Ferrara, N., Ed.; CRC Press, Taylor & Francis Group: Boca Raton, FL, 2007; pp 37–51.
- (2) Yancopoulos, G. D.; Davis, S.; Gale, N. W.; Rudge, J. S.; Wiegand, S. J.; Holash, J. Vascular-specific growth factors and blood vessel formation. *Nature* **2000**, *407*, 242–248.
- (3) Ferrara, N. VEGF and the quest for tumour angiogenesis factors. *Nat. Rev. Cancer* **2002**, *2*, 795–803.
- (4) Klagsbrun, M.; D'Amore, P. A. Regulators of angiogenesis. *Annu. Rev. Physiol.* **1991**, *53*, 217–239.
- (5) Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. *Endocr. Rev.* **2004**, *25*, 581–611.
- (6) Cristofanilli, M.; Charnsangavej, C.; Hortobagyi, G. N. Angiogenesis modulation in cancer research: novel clinical approaches. *Nat. Rev. Drug Discovery* **2002**, *1*, 415–426.
- (7) Duda, D. G.; Batchelor, T. T.; Willett, C. G.; Jain, R. K. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. *Trends Mol. Med.* **2007**, *13*, 223–230.
- (8) Midgley, R.; Kerr, D. Bevacizumab-current status and future directions. *Ann. Oncol.* **2005**, *16*, 999–1004.
- (9) Ferrara, N.; Hillan, K. J.; Novotny, W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. *Biochem. Biophys. Res. Commun.* **2005**, *333*, 328–335.
- (10) Shih, T.; Lindley, C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. *Clin. Ther.* **2006**, *28*, 1779–1802.
- (11) Krämer, I.; Lipp, H. P. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. *J. Clin. Pharm. Ther.* **2007**, *32*, 1–14.
- (12) Tuncbilek, N.; Karakas, H. M.; Okten, O. O. Dynamic contrast enhanced MRI in the differential diagnosis of soft tissue tumors. *Eur. J. Radiol.* **2005**, *53*, 500–505.
- (13) Marzola, P.; Degrassi, A.; Calderan, L.; Farace, P.; Nicolato, E.; Crescimanno, C.; Sandri, M.; Giusti, A.; Pesenti, E.; Terron, A.; Sbarbati, A.; Osculati, F. Early antiangiogenic activity of U11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. *Clin. Cancer Res.* **2005**, *11*, 5827–5832.
- (14) Thoeny, H. C.; De Keyser, F.; Vandecaveye, V.; Chen, F.; Sun, X.; Bosmans, H.; Hermans, R.; Verbeken, E. K.; Boesch, C.; Marchal, G.; Landuyt, W.; Ni, Y. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. *Radiology* **2005**, *237*, 492–499.
- (15) Daldrop, H.; Shames, D. M.; Wendland, M.; Okuhata, Y.; Link, P. M.; Rosenau, W.; Lu, Y.; Brasch, R. C. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. *Am. J. Roentgenol.* **1998**, *171*, 941–949.
- (16) de Lussanet, Q. G.; Langereis, S.; Beets-Tan, R. G.; et al. Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. *Radiology* **2005**, *235*, 65–72.
- (17) Fan, X.; Medved, M.; River, J. N.; Zamora, M.; Corot, C.; Robert, P.; Bourrinet, P.; Lipton, M.; Culp, R. M.; Karczmar, G. S. New model for analysis of dynamic contrast-enhanced MRI data distinguishes metastatic from nonmetastatic transplanted rodent prostate tumors. *Magn. Reson. Med.* **2004**, *51*, 487–494.
- (18) Bhujwalla, Z. M.; Artemov, D.; Natarajan, K.; Solaiyappan, M.; Kollars, P.; Kristjansen, P. E. Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. *Clin. Cancer Res.* **2003**, *9*, 355–362.
- (19) Marzola, P.; Degrassi, A.; Calderan, L.; Farace, P.; Nicolato, E.; Crescimanno, C.; Sandri, M.; Giusti, A.; Pesenti, E.; Terron, A.; Sbarbati, A.; Osculati, F. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. *Clin. Cancer Res.* **2005**, *11*, 5827–5832.
- (20) Schmiedl, U.; Ogan, M.; Paajanen, H.; Marotti, M.; Crooks, L.; Brito, A.; Brasch, R. Albumin labeled with Gd-DTPA as an intravascular, blood pool-enhancing agent for MRI: biodistribution and imaging studies. *Radiology* **1987**, *162*, 205–210.
- (21) Lu, Z.-R.; Mohs, A. M.; Zong, Y.; Feng, Y. Polydisulfide Gd(III) chelates as biodegradable macromolecular magnetic resonance imaging contrast agents. *Intl. J. Nanomed.* **2006**, *1*, 31–40.
- (22) Zong, Y.; Wang, X.; Goodrich, K. C.; Mohs, A. M.; Parker, D. L.; Lu, Z. R. Contrast-enhanced MRI with new biodegradable macromolecular Gd(III) complexes in tumor-bearing mice. *Magn. Reson. Med.* **2005**, *53*, 835–842.
- (23) Zong, Y.; Ke, T.; Mohs, A. M.; Guo, J.; Parker, D. L.; Lu, Z.-R. Effect of size and charge on in vivo MRI contrast enhancement of polydisulfide Gd(III) complexes. *J. Controlled Release* **2006**, *112*, 350–356.
- (24) Kaneshiro, T.; Ke, T.; Jeong, E. K.; Parker, D. L.; Lu, Z.-R. (Gd-DTPA)-(L-cystine bisalkylamide) copolymers as novel biodegradable macromolecular contrast agents for MR blood pool imaging. *Pharm. Res.* **2006**, *23*, 1285–1294.

excrete from the body via renal glomerular filtration.^{25–28} The biodegradable macromolecular MRI contrast agents have minimal tissue accumulation comparable to the clinical contrast agents. The biodegradable macromolecular contrast agents are also effective for quantitative characterization of tumor vascularity in DCE-MRI.²⁹

In this study, we investigated the effectiveness of a biodegradable macromolecular MRI contrast agent, Gd-DTPA cystamine copolymers (GDCC), for assessing tumor microvascular changes in antiangiogenic treatment using an experimental human colon cancer model. A low molecular weight clinical contrast agent, Gd(DTPA-BMA) (MW = 574 Da), was used as a low molecular weight control. Tumor vascular parameters, K^{trans} and f^{PV} , were determined by DCE-MRI with both agents before and after the treatment with Avastin. The tumor vascular parameters were evaluated in correlation to the tumor growth before and after the treatment.

Experimental Section

Animal Models. The animal study was performed according to an animal study protocol approved by the Institutional Animal Care and Use Committee of the University of Utah. HT-29 human colon carcinoma cell line was purchased from American Type Culture Collection (ATCC, Manassas, VA). HT-29 cell line was cultured using ATCC complete growth medium (5 McCoy's Medium with 10% fetal bovine serum). Athymic female NCr-nu/nu nude mice (4–6 weeks old) were purchased from National Cancer Institute at Frederick, MD. The suspension of HT-29 cells in complete medium was mixed with Matrigel matrix (BD Biosciences, San Jose, CA) at 1:1 ratio. The mixtures (2×10^6 cells, 100 μL) were implanted subcutaneously in the flank of 12 mice when the mice were approximately 10–12 weeks old.

Contrast Agents. Gd-DTPA cystamine copolymers (GDCC) were prepared as previously described.²⁸ The

polymers were fractionated using a Superose 6 column on a Pharmacia FPLC system (Gaithersburg, MD) to prepare the contrast agent with narrow molecular weight distributions. The average molecular weights of the fractions were determined by size exclusion chromatography using poly[N-(2-hydroxypropyl)methacrylamide] as standard on an AKTA FPLC system (GE Biosciences, Piscataway, NJ). The fraction with a molecular weight of 40 kDa (GDCC-40) was used in this study. The Gd(III) content in the agents was determined by inductively coupled plasma optical emission spectroscopy (ICP-OES, Perkin-Elmer Optima 3100XL). Gd(DTPA-BMA) (gadodiamide, MW = 574 Da) was obtained from GE Healthcare Inc., Princeton, NJ.

MRI. Mice were anesthetized by intraperitoneal injection of a mixture of ketamine (Bedford, OH, 90 mg/kg) and xylazine (St. Joseph, MO, 10 mg/kg). The mice were then placed with the tumors located approximately at the center of a coil. The anesthetized animals were placed on a heating pad before MRI and then wrapped in warm towels to maintain body temperature. A tail vein of mouse was catheterized with a 30 gauge needle connected with 2.5 m long tubing filled with heparinized saline. The contrast agents (100 μL) were preloaded into the tubing and manually injected within 3 s by flushing with 200 μL of saline. The doses were 0.05 mmol of Gd/kg for GDCC-40 and 0.1 mmol of Gd/kg for Gd(DTPA-BMA). All images were acquired on a whole body clinical 3T MRI system (Tim-Trio, Siemens Medical Solutions, Erlangen, Germany) using a homemade quadrature transmit/receive saddle coil with 1.5 in. inner diameter and 3 in. length. A group of 6 mice with average weights of 21.9 ± 1.3 g was used for each agent.

Three-dimensional MR images were acquired using a 3D turboFLASH sequence, followed by a 2D T_1 -weighted spin-echo sequence before injection of the contrast agent. The 3D turboFLASH images were used to define the slice location for the 2D SE images. Dynamic MRI was performed to rapidly acquire 20 coronal slices with a 2D turboFLASH sequence for a period of 20 min with the temporal resolution of 6.0 s. After a delay of approximately 2 min of precontrast imaging, the contrast agents were administered into the tail vein via the catheter. Twenty 2D coronal SE images were then acquired for 20 min after the injection. Parameters of the 3D turboFLASH sequence were TR/TE = 7.40/2.60 ms, $\alpha = 25^\circ$, FOV = $52 \times 120 \times 24$ mm³ and matrix = $112 \times 256 \times 48$ yielding $0.47 \times 0.47 \times 0.5$ mm³ spatial resolution. Imaging parameters for 2D SE sequence were TR/TE = 600/13 ms, $\alpha = 90^\circ$, FOV = 35×102 and acquisition matrix = 88×256 yielding 0.4×0.4 mm² in-plane resolution with 0.8 mm slice thickness. The parameters of 2D turboFLASH sequence for DCE-MRI were TR/TE = 5.80/2.10 ms, $\alpha = 25^\circ$, FOV = 51×102 and acquisition matrix = 64×128 yielding 0.8×0.8 mm² in-plane resolution with 0.8 mm thickness for total 20 slices that include a few slices covering the heart. Imaging time of each time frame was 6 s in DCE-MRI.

Evaluation of the Antiangiogenic Efficacy of Avastin with DCE-MRI. The DCE-MRI study and treatment with Avastin were performed when the tumors reached ap-

- (25) Wang, X.; Feng, Y.; Ke, T.; Schabel, M.; Lu, Z.-R. Pharmacokinetics and tissue retention of (Gd-DTPA)-cystamine copolymers, a biodegradable macromolecular magnetic resonance imaging contrast agent. *Pharm. Res.* **2005**, *22*, 596–602.
- (26) Feng, Y.; Zong, Y.; Ke, T.; Jeong, E. K.; Parker, D. L.; Lu, Z.-R. Pharmacokinetics, biodistribution and contrast enhanced MR blood pool imaging of Gd-DTPA cystine copolymers and Gd-DTPA cystine diethyl ester copolymers in a rat model. *Pharm. Res.* **2006**, *23*, 1736–1742.
- (27) Mohs, A.; Nguyen, T.; Jeong, E. K.; Feng, Y.; Emerson, L.; Zong, Y.; Parker, D. L.; Lu, Z.-R. Modification of Gd-DTPA cystine copolymers with PEG-1000 optimizes pharmacokinetics and tissue retention for magnetic resonance angiography. *Magn. Reson. Med.* **2007**, *58*, 110–118.
- (28) Lu, Z.-R.; Parker, D. L.; Goodrich, K. C.; Wang, X.; Dalle, J. G.; Buswell, H. R. Extracellular biodegradable macromolecular gadolinium (III) complexes for MRI. *Magn. Reson. Med.* **2004**, *51*, 27–34.
- (29) Feng, Y.; Jeong, E.-K.; Mohs, A.; Emerson, L.; Lu, Z.-R. Characterization of tumor angiogenesis with dynamic contrast enhanced magnetic resonance imaging and biodegradable macromolecular contrast agents in mice. *Magn. Reson. Med.* **2008**, *60*, 1347–1352.

proximately 1 cm in long diameter, about 3 weeks after tumor cell inoculation. A group of six mice each were used for DCE-MRI with GDCC-40 and the control agent Gd(DTPA-BMA). DCE-MRI experiment was performed before the treatment to determine the pretreatment values of tumor vascular parameters with both agents. Avastin (Bevacizumab, Genentech, South San Francisco, CA) was then intraperitoneally injected at a dose of 200 $\mu\text{g}/\text{mouse}$ every 2 days for 6 days starting on the day 22 of tumor implantation. DCE-MRI with both agents was performed at 36 h and 7 days after the first injection of Avastin. Tumor size was measured using a caliper during the study. Tumor volume was calculated using equation $V = AB^2/2$, where A is long diameter, B is short diameter.

Analysis of DCE-MRI Data. The 3D FLASH and 2D SE images were reconstructed and analyzed using Osirix software (<http://homepage.mac.com/rossetantoine/osirix/>). A package of programs based on MATLAB (The MathWorks, Inc., Natick, MA) was developed to process dynamic 2D FLASH data in DICOM format. Regions of interest (ROIs) were manually drawn at least six times at the right ventricle of the heart or tumor periphery for each image slice. The right ventricle of the heart was selected as ROI to obtain blood signal intensity (SI) or arterial input function. ROIs were limited to the tumor periphery for kinetic analysis because the tumor periphery is highly vascularized with angiogenic microvessels.¹⁵ The tumor periphery was defined as the periphery zone of strong contrast enhancement. ROIs were also selected at the inner tumor tissues to study the changes of vascular parameters. The average signal intensity of the precontrast images (SI_0) in the ROIs was used as the pretreatment value. Signal enhancements after contrast injection were calculated as: $\Delta SI_t = (SI_t - SI_0)/SI_0$, where SI_t is the signal intensity within the ROIs at the time t postcontrast. It is assumed that ΔSI is proportional to the change of the contrast agent concentration, which is a reasonable approximation at low contrast agent concentration.³⁰

The signal-time kinetic data were analyzed using a two-compartment bidirectional exchange kinetic model as shown in eq 1,¹⁵

$$C_T(t) = K^{\text{trans}} \int_0^t C_p(\theta) e^{-k_{\text{ep}}(t-\theta)} d\theta + f^{\text{PV}} C_p(t) \quad (1)$$

where $C_p(t)$ and $C_T(t)$ are the contrast agent concentrations in plasma and in the tumor, respectively. The concentration in blood, $C_B(t)$, were first converted to $C_p(t)$ by dividing by $(1 - \text{Hct})$, where Hct is the hematocrit of mice. According to the literature,³¹ an average hematocrit value 0.42 was used in this study. K^{trans} is the endothelial transfer coefficient, K_{ep} the rate constant of reflux from the extravascular and extracellular space (EES) back to blood, θ a Laplace operator and f^{PV} the fractional plasma volume. The vascular param-




Figure 1. Tumor volume and normalized tumor growth percentage relative to the tumor size of day 20 (inset) before and after treatment with Avastin. Treatment was started on day 22 by ip administration of Avastin at a dose of 200 $\mu\text{g}/\text{mouse}$ every 2 days in 6 days. 1: First treatment. 2: Second treatment. 3: Third treatment. Tumor growth was temporarily arrested by initial administration of Avastin and then resumed at a slower rate even after the second and third administrations.

eters K^{trans} and f^{PV} in the tumor periphery were estimated by fitting the signal enhancement values of blood in the heart and tumor periphery using a nonlinear algorithm. Detailed pixel-by-pixel analysis was also performed in the tumor tissue to construct K^{trans} and f^{PV} maps in the tumor tissues.

Histologic Analysis. Mice were sacrificed at the end of the experiment, and tumors were excised and fixed in 10% formaldehyde solution for about 3 days. Then the tumor was cut in half along the midline of tumor in the coronal plane corresponding to that used for the MR images and embedded in paraffin. From each of the two halves, six consecutive sections (5 μm thick) were sliced. One half was stained with conventional hematoxylin–eosin and the other half was stained with antibody to factor VIII. All sections were examined with microscopy. Tumor necrotic area, viable tumor cells and microvessel density were assessed and compared between the pretreated and post-treated tumors.

Statistics Analysis. Statistical analysis was performed using a paired two-tailed Student's t test (GraphPad Prism; GraphPad Software, San Diego, CA). A confidence interval of 95% ($p < 0.05$) was considered statistically significant. The tumor vascular parameters, K^{trans} and f^{PV} , were compared before and after the treatment.

Results

Figure 1 shows the tumor growth curve of the mice before and after treatment with Avastin. The HT-29 colon tumor

(30) Shames, D. M.; Kuwatsuru, R.; Vexler, V.; Muhler, A.; Brasch, R. C. Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging: a quantitative noninvasive technique. *Magn. Reson. Med.* **1993**, *29*, 616–622.

(31) Trune, D. R.; Kempton, J. B.; Gross, N. D. Mineralocorticoid receptor mediates glucocorticoid treatment effects in the autoimmune mouse ear. *Hear. Res.* **2006**, *212*, 22–32.




Figure 2. Representative contrast enhancement–time curves in plasma and tumor for GDCC-40 (A, B) and Gd(DTPA-BMA) (C, D) before and 36 h and 7 days after the first administration of Avastin.

xenografts grew rapidly, and the average tumor volume reached about $508 \pm 185 \text{ mm}^3$ 3 weeks after inoculation (right before Avastin treatment). Treatment was started on day 22 by ip administration of Avastin at a dose of $200 \mu\text{g}/\text{mouse}$ every 2 days in 6 days. The variation of tumor volume is relatively large due to different tumor size from different mice. The inset of Figure 1 shows the normalized tumor growth percentage relative to the tumor size of day 20. Before treatment, tumor growth was significant ($p < 0.01$) when the tumor size of days 20 and 22 was compared. After the first treatment, tumor growth was reduced with no significant difference ($p = 0.44$) when the tumor size of days 22 and 24 was compared. After the second and third treatments, tumor growth became significant again ($p < 0.05$). This result showed that tumor growth was temporarily arrested by the initial administration of Avastin and then resumed after the second and third administrations at a slower rate.

Figure 2 shows the representative arterial input function and signal enhancement (ΔSI)–time curves in the tumor periphery for GDCC-40 and Gd(DTPA-BMA) before and at 36 h and 7 days after the first administration of Avastin. The arterial input function showed that both agents have a high initial concentration after the injection. The low molecular weight Gd(DTPA-BMA) was then rapidly cleared from blood, while GDCC-40 was cleared at a relatively slow rate. At 36 h after the first administration, the initial signal enhancement in tumor periphery with GDCC-40 decreased to approximately 50% of the baseline enhancement (pretreatment). The initial signal enhancement increased slightly at 7 days after three injections as compared to those measured at 36 h after the first injection. However, the initial signal

enhancement with Gd(DTPA-BMA) did not show significant changes of Gd(DTPA-BMA) uptake in tumor periphery before and after the treatment with Avastin.

The vascular parameters K^{trans} and f^{PV} in the tumor periphery were calculated from the signal enhancement (ΔSI)–time data for each mouse before and after the treatment. Table 1 summarizes the average values of K^{trans} and f^{PV} in both tumor periphery and inner tumor tissue estimated from DCE-MRI with GDCC-40 and Gd(DTPA-BMA). Figure 3 plots the K^{trans} and f^{PV} parameters estimated from the agents before and after the treatments with Avastin. Both K^{trans} and f^{PV} values in tumor periphery obtained from DCE-MRI with GDCC-40 significantly decreased at 36 h after the first treatment as compared to the pretreatment values ($p < 0.05$). The values increased at 7 days after three treatments and were similar to the pretreatment values ($p > 0.05$). The average K^{trans} in the tumor core did not change significantly after the treatment as compared to the pretreatment values. The average f^{PV} in the tumor core after the treatment decreased significantly from the pretreatment values. In comparison, the K^{trans} and f^{PV} in both tumor periphery and tumor core estimated from DCE-MRI with Gd(DTPA-BMA) after treatments were not significantly different from the pretreatment values ($p > 0.05$). The K^{trans} and f^{PV} values estimated from Gd(DTPA-BMA) were also much higher than those estimated from GDCC-40.

Figure 4 shows the representative color-coded K^{trans} and f^{PV} maps of tumor tissues constructed based on pixel-by-pixel analysis before and after the treatment with Avastin. The maps revealed that tumor periphery had higher K^{trans} and f^{PV} values than the inner tumor tissues in all cases. The vascular parameters in the tumor periphery estimated from DCE-MRI with GDCC-40 were smaller than those estimated from Gd(DTPA-BMA). The number of pixels with high K^{trans} and f^{PV} values decreased after the treatment as shown in the maps from GDCC-40 as compared to those of pretreatment. However, vascular parameter values in tumor periphery at 7 days after the treatment were higher than those at 36 h after the first treatment (Figure 4A). The K^{trans} maps from DCE-MRI with Gd(DTPA-BMA) also revealed the reduction of pixel numbers of high K^{trans} values in the inner tumor tissue after the treatment, while the K^{trans} values in the tumor periphery remained high (Figure 4B). No significant difference was shown in the f^{PV} maps from Gd(DTPA-BMA) before and after the treatment.

Discussion

Antiangiogenic therapy is a new strategy for cancer treatment, which targets tumor vasculature and inhibits tumor angiogenesis. Several antiangiogenesis therapeutic agents have been approved by the FDA for cancer treatment.^{7–11} More new agents are in various stages of preclinical and clinical development. Noninvasive imaging biomarkers can provide early and accurate evaluation of therapeutic efficacy of these agents, which is crucial for identification of suitable agents in preclinical drug development, and for patient management and efficacious cancer treatment in image-

Table 1. Tumor Vascular Parameters Determined by DCE-MRI before and after Administration of Avastin

	GDCC-40			Gd(DTPA-BMA)		
	pre	post		pre	post	
		36 h	7 days		36 h	7 days
	K^{trans} (mL of plasma/mL of tissue/min)					
tumor periphery	0.014 ± 0.002	0.009 ± 0.005* ^a	0.017 ± 0.014	0.072 ± 0.024	0.065 ± 0.036	0.083 ± 0.038
tumor core	0.008 ± 0.003	0.006 ± 0.005	0.007 ± 0.009	0.032 ± 0.008	0.022 ± 0.007	0.028 ± 0.007
	f^{PV} (mL of plasma/ mL of tissue)					
tumor periphery	0.029 ± 0.006	0.011 ± 0.007*	0.023 ± 0.025	0.109 ± 0.035	0.058 ± 0.033	0.100 ± 0.052
tumor core	0.013 ± 0.005	0.003 ± 0.005*	0.004 ± 0.003	0.061 ± 0.053	0.027 ± 0.020	0.022 ± 0.015

^a (*) Statistically significant from pretreatment values ($p < 0.05$).




Figure 3. Graphs showing change in K^{trans} (A) and f^{PV} (B) for GDCC-40 and Gd(DTPA-BMA) before and after Avastin administration. *: $P < 0.05$. K^{trans} = endothelial transfer coefficient (mL of plasma/mL of tissue/min), f^{PV} = fractional vascular volume (mL of plasma/mL of tissue).

guided cancer therapy. In this study, we investigated the effectiveness of a biodegradable macromolecular MRI contrast agent, GDCC-40, for assessing tumor microvascular changes in antiangiogenic treatment with DCE-MRI in an animal tumor model. We have shown that DCE-MRI with GDCC-40 is effective for noninvasive and early evaluation of antiangiogenic therapy based on the estimated vascular parameters.

Avastin is a humanized anti-VEGF-A antibody approved by the FDA to treat metastatic colorectal cancer, metastatic breast cancer and nonsmall cell lung cancer in combination with chemotherapies. It blocks tumor angiogenesis and inhibits tumor growth. The administration of Avastin to mice bearing HT-29 human colon adenocarcinoma xenografts resulted in initial arrest of tumor growth after the first injection and then a relatively slow growth rate after further injections (Figure 1). The body weight of the mice was also monitored at each time point of MRI scan (before and 36 h

and 7 days after Avastin therapy). Compared to the body weight of the mice at the first MRI scan (21.9 ± 1.3 g), there was no difference at the second (21.5 ± 1.2 g, $p = 0.43$) or third (21.6 ± 1.8 g, $p = 0.68$) MRI scan. This indicated that the health of the mice was not affected by the anesthesia or restraint during MRI scan, and the decreased tumor growth rate should be from the effect of Avastin therapy.

The low therapeutic efficacy after the second and third administrations might be attributed to the fact that Avastin neutralizes human VEGF-A^{32–34} and might not be effective in neutralizing mouse VEGF-A and other forms of mouse VEGF. In this study, human tumor xenografts were implanted in mice and Avastin might initially neutralize the human VEGF-A. A compensatory upregulated murine VEGF released by the host might be responsible for the tumor angiogenesis and regrowth.³⁵ Furthermore, Avastin could not neutralize other members of the VEGF gene family, including VEGF-B and VEGF-C, which may also play important roles in stimulating tumor angiogenesis and regrowth.^{1,2,33,36–38}

DCE-MRI with GDCC-40 was able to measure the changes of tumor vascular parameters, vascular permeability (K^{trans}) and fractional tumor plasma volume (f^{PV}), in correlation to therapeutic efficacy of Avastin in the animal tumor model. A significant decrease of K^{trans} and f^{PV} was observed

(32) Presta, L. G.; Chen, H.; O'Connor, S. J.; Chisholm, V.; Meng, Y. G.; Krummen, L.; Winkler, M.; Ferrara, N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. *Cancer Res.* **1997**, *57*, 4593–4599.

(33) Ferrara, N.; Hillan, K. J.; Novotny, W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. *Biochem. Biophys. Res. Commun.* **2005**, *333*, 328–335.

(34) Ferrara, N.; Hillan, K. J.; Gerber, H. P.; Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. *Nat. Rev. Drug Discovery* **2004**, *3*, 391–400.

(35) Gerber, H. P.; Kowalski, J.; Sherman, D.; Eberhard, D. A.; Ferrara, N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. *Cancer Res.* **2000**, *60*, 6253–6258.

(36) Stoeltzing, O.; Liu, W.; Reinmuth, N.; Parikh, A.; Ahmad, S. A.; Jung, Y. D.; Fan, F.; Ellis, L. M. Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis. *Ann. Surg. Oncol.* **2003**, *10*, 722–733.




Figure 4. Representative color-coded maps of K^{trans} and f^{PV} values measured for the voxels in the central section through the tumor. A is from the tumor of the GDCC-40 injection group, and B is from the tumor of the Gd(DTPA-BMA) injection group.

in viable tumor periphery with high angiogenesis at 36 h after the first injection as compared to the pretreatment values ($p < 0.05$). The estimated K^{trans} and f^{PV} values then increased at 7 days after 3 administrations of Avastin as tumor started regrowth, and became similar to the pretreatment values ($p > 0.05$). No significant changes were observed for the vascular parameters in tumor periphery estimated by DCE-MRI with Gd(DTPA-BMA) before and after the treatment

with Avastin ($p > 0.05$), because the agent nonselectively permeated through both normal and angiogenic blood vessels.

Macromolecular MRI contrast agents have been shown more effective than small molecular ones for characterization of tumor angiogenesis and evaluation of therapeutic efficacy of antiangiogenesis therapies.^{18,19,39,40} However, clinical development of macromolecular contrast agents is limited by their slow excretion and consequent potential toxic side

effects. Biodegradable macromolecular agents based on polydisulfide Gd(III) chelates have been developed to facilitate the excretion after the MRI studies. Due to their degradability in plasma, these agents have relatively short blood half-lives as compared to the nondegradable macromolecular contrast agents. However, the degradation of GDCC was relatively slow in the first 20 min in the incubation with fresh rat plasma,^{28,41} which was the duration of DCE-MRI experiment of this study. The biodegradable macromolecular contrast agent still behaved as a macromolecular contrast agent in the initial period of DCE-MRI study for effective evaluation of therapeutic efficacy.⁴² Our previous studies have shown that the vascular parameters estimated by DCE-MRI with the biodegradable macromolecular contrast agents were slightly higher than those estimated with albumin-(Gd-DTPA), but lower than those estimated with a

low molecular weight clinical contrast agent.²⁹ This study has shown that the biodegradable macromolecular contrast agent GDCC-40 was able to provide early assessment of the tumor response to antiangiogenic therapy in DCE-MRI based on estimated vascular parameters. Since GDCC-40 initially behaved as a macromolecular contrast agent, it was able to effectively estimate the changes in tumor vascular permeability to macromolecules in DCE-MRI, particularly in highly angiogenic tumor periphery.

This is the first attempt to evaluate the potential of the biodegradable macromolecular contrast agents in early assessment of tumor response to antiangiogenesis therapy. This study had several limitations. The DCE-MRI sequence we used was not able to accurately measure the kinetic changes of the concentrations of contrast agents. Our previous studies showed that the relaxivities of the biodegradable macromolecular contrast agent GDCC did not vary substantially with different molecular weights. Therefore, the relaxivities of GDCC were considered constant during the period of experiment. In this study, we did not observe any significant changes in tumor microvessel density before and after the treatment with Avastin in histological studies. The histological data did not correlate to the tumor vascular parameters estimated with DCE-MRI and GDCC-40 and the tumor growth curve. Further and more broadly designed studies covering various preclinical and clinical conditions are required to validate the effectiveness of the biodegradable contrast agent in the early assessment of tumor response to cancer therapies.

In conclusion, the biodegradable macromolecular contrast agent GDCC-40 was effective to estimate the changes of the tumor vascular parameters before and after the treatment with antiangiogenic therapeutics in DCE-MRI. DCE-MRI with GDCC-40 has the potential to noninvasively assess early tumor response to antiangiogenic therapy and to follow the therapeutic efficacy in the treatment.

Acknowledgment. The authors thank Dr. Yong-En Sun for the animal handling, Dr. James Lee for technical assistance in MRI data acquisition, and Oliver Jeong for making the quadrature transmit/receive saddle coil. This work was supported in part by the NIH Grant R01 EB00489.

MP900153F

- (37) Bruns, C. J.; Solorzano, C. C.; Harbison, M. T.; Ozawa, S.; Tsan, R.; Fan, D.; Abbruzzese, J.; Traxler, P.; Buchdunger, E.; Radinsky, R.; Fidler, I. J. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. *Cancer Res.* **2000**, *60*, 2926–2935.
- (38) Yuan, F.; Chen, Y.; Dellian, M.; Safabakhsh, N.; Ferrara, N.; Jain, R. K. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. *Proc. Natl. Acad. Sci. U.S.A.* **1996**, *93*, 14765–14770.
- (39) Jordan, B. F.; Runquist, M.; Raghunand, N.; Baker, A.; Williams, R.; Kirkpatrick, L.; Powis, G.; Gillies, R. J. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1 alpha using PX-478. *Neoplasia* **2005**, *7*, 475–485.
- (40) Vogel-Claussen, J.; Gimi, B.; Artemov, D.; Bhujwalla, Z. M. Diffusion-weighted and macromolecular contrast enhanced MRI of tumor response to antivascular therapy with ZD6126. *Cancer Biol Ther.* **2007**, *6*, 1469–1475.
- (41) Zong, Y.; Wang, X.; Jeong, E. K.; Parker, D. L.; Lu, Z.-R. Structural effect on degradability and in vivo contrast enhancement of polydisulfide Gd(III) complexes as biodegradable macromolecular contrast agents. *Magn. Reson. Imaging* **2009**, *27*, 503–11.
- (42) Feng, Y.; Emerson, L.; Jeong, E. K.; Parker, D. L.; Lu, Z. R. Non-invasive assessment of the efficacy of indocyanine green enhanced photothermal cancer therapy with dynamic contrast enhanced MRI using a biodegradable macromolecular contrast agent. *J. Magn. Reson. Imaging* **2009**, *27*, 401–6.